The world will need more than one COVID-19 vaccine, so pharmaceutical companies must participate in the race to develop weapons to fight the novel coronavirus, said Emma Walmsley, chief executive officer of GlaxoSmithKline on Wednesday.
GlaxoSmithKline Plc and Sanofi SA said on Tuesday they would develop a vaccine against the rapidly spreading coronavirus.
Drug manufacturers expect to begin clinical trials for the vaccine in the second half of this year. If successful, the vaccine would be available in the second half of 2021.
Walmsley said that GSK's partnership with Sanofi is pushing for a COVID-19 vaccine, but there is still a lot of work to be done.
"The world will definitely need more than one vaccine if you think of the demand in this extremely difficult global health crisis," she told BBC Radio.
The adjuvant vaccine is developed by combining Sanofi's S-protein COVID-19 antigen and GSK's pandemic adjuvant technology.
"It usually takes a decade, sometimes even longer, to develop a vaccine, but obviously we are in an unprecedented situation. The need is incredibly urgent. We are working with regulators to try to go as quickly as possible. "
(Except for the headline, this story was not edited by NDTV staff and published from a syndicated feed.)